ViroPharma (VPHM)
ViroPharma Market Cap: 1.425B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VPHM Market Cap Rankings
| Overall | 66th percentile | 1554 of 4664 |
| Sector | 77th percentile | 120 of 527 in Healthcare |
| Industry | 85th percentile | 23 of 164 in Biotechnology |
VPHM Market Cap Range, Past 5 Years
| Minimum | 406.40M | Mar 2009 |
| Maximum | 2.127B | Mar 2012 |
| Average | 1.044B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these VPHM related companies
VPHM News
Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates ViroPharma, Inc. For Securities Fraud
May 31, 7:45AM Business Wire
May 31, 7:45AM Business Wire
Izard Nobel LLP Announces Class Action Lawsuit Against ViroPharma Incorporated
May 24, 4:59PM Marketwire
May 24, 4:59PM Marketwire
Pomerantz Law Firm Has Filed a Class Action Against ViroPharma Incorporated -- VPHM
May 22, 6:25PM GlobeNewswire
May 22, 6:25PM GlobeNewswire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ViroPharma Incorporated
May 18, 12:58PM Business Wire
May 18, 12:58PM Business Wire
$VPHM Market does seem to be pricing in the decimation of Vancocin. http://stks.co/3c6k
about 31 days ago by birllc
about 31 days ago by birllc
Video of our entry ideas today in $AKAM $VPHM $AIG $NI $MAS $HUN $TSL - http://stks.co/3byB
about 31 days ago by greatstockpix
about 31 days ago by greatstockpix
$VECO up 12% on earnings. $VPHM down 10%. $DEXO continues its descent into oblivion, down 10% to $0.87.
about 31 days ago by MagicDiligence
about 31 days ago by MagicDiligence
Listen to $VPHM Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3bA1
about 31 days ago by earningscast
about 31 days ago by earningscast
Viropharma, Inc. (VPHM) Misses Q1 EPS by 5c; Guides FY12 Revs Below Views
May 01, 6:30AM Street Insider
May 01, 6:30AM Street Insider
$VPHM BioLogic Equity Research – ViroPharma Report Library - http://stks.co/3Vwl
about 37 days ago by birllc
about 37 days ago by birllc
Following...fresh face RT @birllc $VPHM - ViroPharma without Vancocin is Breakeven at Best - http://stks.co/3VsM
about 37 days ago by howardlindzon
about 37 days ago by howardlindzon
$VPHM - ViroPharma without Vancocin is Breakeven at Best - http://stks.co/3Vm8
about 37 days ago by birllc
about 37 days ago by birllc
yestereday wuz huge newz 4 $AKRX. this will take market share frum $VPHM soon. already strong earningz without Vanoccin. $20 runup
about 37 days ago by johnkelly
about 37 days ago by johnkelly
ViroPharma To Release 2012 First Quarter Financial Results On May 1, 2012
Apr 23, 4:00PM PR Newswire
Apr 23, 4:00PM PR Newswire
Holzer Holzer & Fistel, LLC Announces Investigation into ViroPharma Incorporated
Apr 20, 4:01PM Business Wire
Apr 20, 4:01PM Business Wire
$VPHM is -5.1% down since open on unusual high volume and -5.9% down since close.
about 46 days ago by TradeBot
about 46 days ago by TradeBot
@johnkelly Haven't really followed the generics. It's not just $AKRX but also $WPI in competition w $VPHM.
about 51 days ago by abubnic
about 51 days ago by abubnic
$VPHM Concern about generic competition for Vancocin, which brings in about 50% of revenue. http://stks.co/3J6j
about 51 days ago by abubnic
about 51 days ago by abubnic
RT @daytrend $VPHM poster child for why many traders don't touch biotechs.
about 51 days ago by jamiemc101
about 51 days ago by jamiemc101
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VPHM | 20.14 | -0.12 | -0.59% | 1.425B |
| VPG | 13.91 | +0.04 | +0.29% | 171.37M |
| VPFG | 15.25 | -0.01 | -0.07% | 513.92M |
| VASC | 11.38 | -0.08 | -0.70% | 189.14M |
| VAR | 58.66 | -1.23 | -2.05% | 6.628B |
| VALV | 0.85 | -0.06 | -6.08% | 14.14M |
| VALU | 12.25 | +0.08 | +0.66% | 121.28M |
| VALE | 18.31 | -0.12 | -0.65% | 58.04B |
| VAL | 48.21 | -0.33 | -0.68% | 4.489B |
| V | 115.20 | -2.29 | -1.95% | 93.67B |